Healthcare M&A » By The Online Investor Staff, updated Mon., Aug. 10, 1:31 AM
Recent mergers and acquisitions in the Healthcare M&A category.
| This Slide: #59 of 100 |
Slide #59. Retrophin — Manchester Pharmaceuticals
Acquirer:
Retrophin (NASDAQ:RTRX)
Acquiree:
Manchester Pharmaceuticals
Details:
Retrophin, Inc. (NASDAQ:RTRX) today announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5 million, including an upfront payment of $29.5 million, plus other payments based on product sales.
Retrophin is a biopharmaceutical company focused on identifying, developing and delivering therapies to people living with rare diseases. Co.'s commercialized products include Chenodal (chenodiol tablets) for the treatment of radiolucent stones in well-opacifying gallbladders in patients; Cholbam (cholic acid capsules), a treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC (tiopronin), a treatment for cystinuria, a genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
RTRX SEC Filing Email Alerts Service
Open the RTRX Page at The Online Investor »
|
|||||||||||||||||||||
Open the RTRX Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
 
|
Strong Buy (3.71 out of 4) 73rd percentile
(ranked higher than approx. 73% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
